By Jeff Overley (January 13, 2014, 5:28 PM EST) -- The U.S. Food and Drug Administration on Monday delivered a small portion of long-awaited guidance on how drugmakers can properly promote their products via social media like Twitter, although key questions remain unanswered for now.
In a 10-page document, the FDA focused primarily on when manufacturers are responsible for the content of promotional material and how such communications should be provided to regulators for review.
Left unaddressed were how risks can be communicated within the character-space confines of Twitter, what constitutes acceptable use of hyperlinks, and how much responsibility drugmakers have to correct misstatements by other entities or individuals.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!